Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Valeo Pharma (DE:VP2)
FRANKFURT:VP2
Holding DE:VP2?
Track your performance easily
VP2 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.03 - €0.26
Previous Close€0.04
Volume0.00
Average Volume (3M)17.33K
Market Cap
€6.97M
Enterprise Value€29.77M
Total Cash (Recent Filing)C$9.59M
Total Debt (Recent Filing)C$43.47M
Price to Earnings (P/E)―
Beta-1.76
Next Earnings
Sep 11, 2024EPS Estimate
-€0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding98,675,427
10 Day Avg. Volume2,290
30 Day Avg. Volume17,333
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)-0.15
Price to Sales (P/S)0.14
Price to Cash Flow (P/CF)1.70
P/FCF Ratio0.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.34Price Target Upside708.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Valeo Pharma News
PremiumCompany Announcements
Valeo Pharma Undertakes Strategic Restructuring
PremiumCompany Announcements
Valeo Pharma’s Q3 Revenues Dip Amidst Core Growth
PremiumCompany Announcements
Valeo Pharma Schedules Q3 Financial Results Call
PremiumCompany Announcements
Valeo Pharma Revises Loan Terms for Financial Agility
PremiumCompany Announcements
Valeo Pharma Withdraws from OTCQB Market
PremiumCompany Announcements
Valeo Pharma Appoints New CEO; Eyes Expansion
PremiumCompany Announcements
Valeo Pharma Welcomes New Chief Development OfficerBulls Say, Bears Say
Bulls Say
Profitability PathwayCost-saving initiatives and workforce reductions will support the company's pathway to profitability and its timeline of cash flow positivity.
Restructuring AnnouncementThe announcement of a 20% restructuring of the workforce for its fast-growing Respiratory unit will provide annualized savings of over $5 million.
Unit GrowthThe Respiratory unit saw a 52% increase in sales year-over-year, showing strong performance despite other challenges.
Bears Say
Financial PerformanceValeo Pharma reported results that missed on both topline and adjusted EBITDA due to a slowdown in Xiidra sales and delays for Redesca.
FundingValeo ended the quarter with a cash balance of $6.9M, and the company will likely be required to raise additional funds given its existing credit facility and debt obligations.
Gross MarginThe company's gross margin decreased due to a decline in contribution from Xiidra.
---
Options Prices
Currently, No data available
---
Ownership Overview
94.00% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
6.00% Public Companies and
Individual Investors
VP2 FAQ
What was Valeo Pharma’s price range in the past 12 months?
Valeo Pharma lowest stock price was €0.03 and its highest was €0.26 in the past 12 months.
What is Valeo Pharma’s market cap?
Currently, no data Available
When is Valeo Pharma’s upcoming earnings report date?
Valeo Pharma’s upcoming earnings report date is Sep 11, 2024 which is 102 days ago.
How were Valeo Pharma’s earnings last quarter?
Valeo Pharma released its earnings results on Jun 13, 2024. The company reported -€0.054 earnings per share for the quarter, missing the consensus estimate of -€0.034 by -€0.02.
Is Valeo Pharma overvalued?
According to Wall Street analysts Valeo Pharma’s price is currently Undervalued.
Does Valeo Pharma pay dividends?
Valeo Pharma does not currently pay dividends.
What is Valeo Pharma’s EPS estimate?
Valeo Pharma’s EPS estimate is -€0.03.
How many shares outstanding does Valeo Pharma have?
Valeo Pharma has 98,675,430 shares outstanding.
What happened to Valeo Pharma’s price movement after its last earnings report?
Valeo Pharma reported an EPS of -€0.054 in its last earnings report, missing expectations of -€0.034. Following the earnings report the stock price went up 66.667%.
Which hedge fund is a major shareholder of Valeo Pharma?
Currently, no hedge funds are holding shares in DE:VP2
---
Valeo Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.13%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-29.43%
Trailing 12-Months
Company Description
Valeo Pharma
Valeo Pharma Inc a Canadian specialty pharmaceutical company focused on acquiring either through acquisitions, in-licensing or similar arrangements. Its current markets its product Synacthen Depot which is a synthetic ACTH product that is used in conditions where the production of natural cortisol and other hormones is desired.
---
VP2 Earnings Call
Q2 2024
0:00 / 0:00
---
VP2 Stock 12 Month Forecast
Average Price Target
€0.34
▲(708.93% Upside)
Technical Analysis
Best Analysts Covering VP2
1 Year
1 Year Success Rate
0/9 ratings generated profit
1 Year Average Return
-55.84%
reiterated a buy rating 6 months ago
Copying Stefan Quenneville's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -55.84% per trade.
---